1932

Abstract

Current silo-based diagnostic systems for mental disorders lack utility and fail to fulfil a fundamental purpose of diagnosis: to guide treatment planning and predict outcomes. Diagnostic reform has gained momentum, and clinical staging has emerged as a promising framework to improve the precision of diagnosis, particularly in early illness stages, and fill current gaps in linking diagnosis to more personalized and effective intervention, prognosis, and neurobiological markers. Transdiagnostic clinical staging recognizes that the early development of mental ill-health is marked by substantial fluidity and that symptoms may, although not inevitably, evolve into more stable diagnosable syndromes. Staging facilitates the selection of interventions that are proportionate to the current need and risk of illness progression and provides an efficient framework to organize biomarker data and guide service delivery. Here, we provide an overview of transdiagnostic clinical staging and summarize key evidence supporting its ability to integrate biomarkers and guide mental health care.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-devpsych-050620-030405
2021-12-09
2024-06-21
Loading full text...

Full text loading...

/deliver/fulltext/devpsych/3/1/annurev-devpsych-050620-030405.html?itemId=/content/journals/10.1146/annurev-devpsych-050620-030405&mimeType=html&fmt=ahah

Literature Cited

  1. Addington J, Liu L, Farris MS, Goldstein BI, Wang JL et al. 2021. Clinical staging for youth at-risk for serious mental illness: a longitudinal perspective. Early Interv. Psychiatry 15:5118896
    [Google Scholar]
  2. Allott K. 2019. Staging of cognition in psychiatric illness. Clinical Staging in Psychiatry: Making Diagnosis Work for Research and Treatment PD McGorry, IB Hickie 140–71 Cambridge, UK: Cambridge Univ. Press
    [Google Scholar]
  3. Alvarez-Jimenez M, Bendall S, Lederman R, Wadley G, Chinnery G et al. 2013. On the HORYZON: moderated online social therapy for long-term recovery in first episode psychosis. Schizophr. Res. 143:143–49
    [Google Scholar]
  4. Alvarez-Jimenez M, Gleeson JF, Bendall S, Penn DL, Yung AR et al. 2018. Enhancing social functioning in young people at Ultra High Risk (UHR) for psychosis: a pilot study of a novel strengths and mindfulness-based online social therapy. Schizophr. Res. 202:369–77
    [Google Scholar]
  5. Alvarez-Jimenez M, Rice S, D'Alfonso S, Leicester S, Bendall S et al. 2020. A novel multimodal digital service (moderated online social therapy+) for help-seeking young people experiencing mental ill-health: pilot evaluation within a national youth e-mental health service. J. Med. Internet Res. 22:e17155
    [Google Scholar]
  6. Amminger GP, Berger M, Rice SM, Davey CG, Schäfer MR, McGorry PD. 2017. Novel biotherapies are needed in youth mental health. Australas. Psychiatry 25:117–20
    [Google Scholar]
  7. Amminger GP, Chanen AM, Ohmann S, Klier CM, Mossaheb N et al. 2013. Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial. Can. J. Psychiatry 58:402–8
    [Google Scholar]
  8. Amminger GP, Mechelli A, Rice S, Kim SW, Klier CM et al. 2015. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids. Transl. Psychiatry 13:e495
    [Google Scholar]
  9. Amminger GP, Nelson B, Markulev C, Yuen HP, Schäfer MR et al. 2020. The NEURAPRO biomarker analysis: long-chain omega-3 fatty acids improve 6-month and 12-month outcomes in youths at ultra-high risk for psychosis. Biol. Psychiatry 87:243–52
    [Google Scholar]
  10. Amminger GP, Schäfer MR, Klier CM, Slavik JM, Holzer I et al. 2012. Decreased nervonic acid levels in erythrocyte membranes predict psychosis in help-seeking ultra-high-risk individuals. Mol. Psychiatry 17:1150–52
    [Google Scholar]
  11. Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM et al. 2010. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 67:146–54
    [Google Scholar]
  12. Andreazza AC, Kapczinski F, Kauer-Sant'Anna M, Walz JC, Bond DJ et al. 2009. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J. Psychiatry Neurosci. 34:263–71
    [Google Scholar]
  13. Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J et al. 2018. Analysis of shared heritability in common disorders of the brain. Science 360:eaap8757
    [Google Scholar]
  14. Appiah-Kusi E, Petros N, Wilson R, Colizzi M, Bossong MG et al. 2020. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology 237:1121–30
    [Google Scholar]
  15. Assies J, Pouwer F, Lok A, Mocking RJT, Bockting CLH et al. 2010. Plasma and erythrocyte fatty acid patterns in patients with recurrent depression: a matched case-control study. PLOS ONE 5:e10635
    [Google Scholar]
  16. Atkinson RJ, Fulham WR, Michie PT, Ward PB, Todd J et al. 2017. Electrophysiological, cognitive and clinical profiles of at-risk mental state: the longitudinal Minds in Transition (MinT) study. PLOS ONE 12:e0171657
    [Google Scholar]
  17. Bartholomeusz CF, Pantelis C. 2019. Neuroimaging and staging: do disparate mental illnesses have distinct neurobiological trajectories?. Clinical Staging in Psychiatry: Making Diagnosis Work for Research and Treatment PD McGorry, IB Hickie 103–39 Cambridge, UK: Cambridge Univ. Press
    [Google Scholar]
  18. Berger GE, Proffitt T-M, McConchie M, Yuen HP, Wood SJ et al. 2007. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J. Clin. Psychiatry 68:1867–75
    [Google Scholar]
  19. Berger GE, Smesny S, Amminger GP. 2006. Bioactive lipids in schizophrenia. Int. Rev. Psychiatry 18:85–98
    [Google Scholar]
  20. Berger M, Li E, Amminger GP 2020. Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol. BMJ Case Rep 13:e235307
    [Google Scholar]
  21. Berger M, Nelson B, Markulev C, Yuen HP, Schäfer MR et al. 2019. Relationship between polyunsaturated fatty acids and psychopathology in the NEURAPRO clinical trial. Front. Psychiatry 10:393
    [Google Scholar]
  22. Berk M, Conus P, Lucas N, Hallam K, Malhi GS et al. 2007. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord 9:671–78
    [Google Scholar]
  23. Berk M, Copolov D, Dean O, Lu K, Jeavons S et al. 2008. N-acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry 64:361–8
    [Google Scholar]
  24. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F et al. 2011. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 35:804–17
    [Google Scholar]
  25. Berk M, Malhi GS, Gray LJ, Dean OM. 2013. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol. Sci. 34:167–77
    [Google Scholar]
  26. Bhattacharyya S, Wilson R, Appiah-Kusi E, O'Neill A, Brammer M et al. 2018. Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial. JAMA Psychiatry 75:1107–17
    [Google Scholar]
  27. Birnbaum ML, Rizvi AF, Confino J, Correll CU, Kane JM. 2017. Role of social media and the Internet in pathways to care for adolescents and young adults with psychotic disorders and non-psychotic mood disorders. Early Interv. Psychiatry 11:290–95
    [Google Scholar]
  28. Black CN, Bot M, Scheffer PG, Cuijpers P, Penninx BWJH. 2015. Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Psychoneuroendocrinology 51:164–75
    [Google Scholar]
  29. Boggs DL, Surti T, Gupta A, Gupta S, Niciu M et al. 2018. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology 235:1923–32
    [Google Scholar]
  30. Brown NC, Andreazza AC, Young LT. 2014. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res 218:61–68
    [Google Scholar]
  31. Burns J, Birrell E, Bismark M, Pirkis J, Davenport T et al. 2016. The role of technology in Australian youth mental health reform. Aust. Health Rev. 40:584–90
    [Google Scholar]
  32. Calviello G, Su H-M, Weylandt KH, Fasano E, Serini S, Cittadini A. 2013. Experimental evidence of ω-3 polyunsaturated fatty acid modulation of inflammatory cytokines and bioactive lipid mediators: their potential role in inflammatory, neurodegenerative, and neoplastic diseases. Biomed Res. Int. 2013.743171
    [Google Scholar]
  33. Campos AC, Fogaça MV, Sonego AB, Guimarães FS. 2016. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol. Res. 112:119–27
    [Google Scholar]
  34. Carpenter JS, Iorfino F, Cross SP, Davenport TA, Hermens DF et al. 2019. Combining clinical stage and pathophysiological mechanisms to understand illness trajectories in young people with emerging mood and psychotic syndromes. Med. J. Aust. 211:S12–22
    [Google Scholar]
  35. Caspi A, Houts RM, Ambler A, Danese A, Elliott ML et al. 2020. Longitudinal assessment of mental health disorders and comorbidities across 4 decades among participants in the Dunedin birth cohort study. JAMA Netw. Open 3:e203221
    [Google Scholar]
  36. Conus P, Seidman LJ, Fournier M, Xin L, Cleusix M et al. 2018. N-acetylcysteine in a double-blind randomized placebo-controlled trial: toward biomarker-guided treatment in early psychosis. Schizophr. Bull. 44:317–27
    [Google Scholar]
  37. Copoglu US, Virit O, Kokacya MH, Orkmez M, Bulbul F et al. 2015. Increased oxidative stress and oxidative DNA damage in non-remission schizophrenia patients. Psychiatry Res 229:200–5
    [Google Scholar]
  38. Cosci F, Fava GA. 2013. Staging of mental disorders: systematic review. Psychother. Psychosom. 82:20–34
    [Google Scholar]
  39. Cross SP, Davenport TA, Scott EM, Iorfino F, Sawrikar V, Hickie IB. 2019. A service delivery model to support highly personalised and measurement-based care in youth mental health. Med. J. Aust. 211:S42–46
    [Google Scholar]
  40. Cross SPM, Hermens DF, Hickie IB. 2016a. Treatment patterns and short-term outcomes in an early intervention youth mental health service. Early Interv. Psychiatry 10:88–97
    [Google Scholar]
  41. Cross SPM, Hermens DF, Scott EM, Ottavio A, McGorry PD, Hickie IB. 2014. A clinical staging model for early intervention youth mental health services. Psychiatr. Serv. 65:939–43
    [Google Scholar]
  42. Cross SPM, Hermens DF, Scott J, Salvador-Carulla L, Hickie IB. 2016b. Differential impact of current diagnosis and clinical stage on attendance at a youth mental health service. Early Interv. Psychiatry 11:255–62
    [Google Scholar]
  43. Crouse JJ, Carpenter JS, Iorfino F, Lin T, Ho N et al. 2021. Schizophrenia polygenic risk scores in youth mental health: preliminary associations with diagnosis, clinical stage, and functioning. BJPsych Open 7:e58
    [Google Scholar]
  44. Davenport TA, LaMonica HM, Whittle L, English A, Iorfino F et al. 2019. Validation of the InnoWell Platform: protocol for a clinical trial. JMIR Res. Protoc. 8:e13955
    [Google Scholar]
  45. Deepmala, Slattery J, Kumar N, Delhey L, Berk M et al. 2015. Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci. Biobehav. Rev. 55:294–321
    [Google Scholar]
  46. del Re EC, Spencer KM, Oribe N, Mesholam-Gately RI, Goldstein J et al. 2015. Clinical high risk and first episode schizophrenia: auditory event-related potentials. Psychiatry Res. Neuroimaging 231:126–33
    [Google Scholar]
  47. Eggins PS, Hatton SN, Hermens DF, Hickie IB, Lagopoulos J. 2018. Subcortical volumetric differences between clinical stages of young people with affective and psychotic disorders. Psychiatry Res. Neuroimaging 271:8–16
    [Google Scholar]
  48. Erickson MA, Ruffle A, Gold JM. 2016. A meta-analysis of mismatch negativity in schizophrenia: from clinical risk to disease specificity and progression. Biol. Psychiatry 79:980–87
    [Google Scholar]
  49. Fava GA, Kellner R. 1993. Staging: a neglected dimension in psychiatric classification. Acta Psychiatr. Scand. 87:225–30
    [Google Scholar]
  50. Filia K, Rickwood D, Menssink J, Gao CX, Hetrick S et al. 2021. Clinical and functional characteristics of a subsample of young people presenting for primary mental healthcare at headspace services across Australia. Soc. Psychiatry Psychiatr. Epidemiol 56:131123
    [Google Scholar]
  51. Firth J, Rosenbaum S, Ward PB, Curtis J, Teasdale SB et al. 2018. Adjunctive nutrients in first-episode psychosis: a systematic review of efficacy, tolerability and neurobiological mechanisms. Early Interv. Psychiatry 12:774–83
    [Google Scholar]
  52. Firth J, Torous J, Stubbs B, Firth JA, Steiner GZ et al. 2019. The “online brain”: how the Internet may be changing our cognition. World Psychiatry 18:119–29
    [Google Scholar]
  53. Fraguas D, Díaz-Caneja CM, Ayora M, Hernández-Álvarez F, Rodríguez-Quiroga A et al. 2019. Oxidative stress and inflammation in first-episode psychosis: a systematic review and meta-analysis. Schizophr. Bull. 45:742–51
    [Google Scholar]
  54. Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D et al. 2006. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J. Clin. Psychiatry 67:1954–67
    [Google Scholar]
  55. Fusar-Poli P, Rocchetti M, Sardella A, Avila A, Brandizzi M et al. 2015. Disorder, not just state of risk: meta-analysis of functioning and quality of life in people at high risk of psychosis. Br. J. Psychiatry 207:198–206
    [Google Scholar]
  56. Geraets CNW, Snippe E, van Beilen M, Pot-Kolder RMCA, Wichers M et al. 2020. Virtual reality based cognitive behavioral therapy for paranoia: effects on mental states and the dynamics among them. Schizophr. Res. 222:227–34
    [Google Scholar]
  57. Gibb SJ, Fergusson DM, Horwood LJ. 2010. Burden of psychiatric disorder in young adulthood and life outcomes at age 30. Br. J. Psychiatry 197:122–27
    [Google Scholar]
  58. Goldsmith DR, Rapaport MH, Miller BJ. 2016. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol. Psychiatry 21:1696–709
    [Google Scholar]
  59. Gonnella JS, Hornbrook MC, Louis DZ. 1984. Staging of disease: a case-mix measurement. JAMA 251:637–44
    [Google Scholar]
  60. Goodkind M, Eickhoff SB, Oathes DJ, Jiang Y, Chang A et al. 2015. Identification of a common neurobiological substrate for mental illness. JAMA Psychiatry 72:305–15
    [Google Scholar]
  61. Grierson AB, Scott J, Glozier N, Hickie IB, Amminger PG et al. 2019. Can youth at high risk of illness progression be identified by measures of rumination and sleep-wake disturbance. Early Interv. Psychiatry 13:1214–19
    [Google Scholar]
  62. Hallahan B, Ryan T, Hibbeln JR, Murray IT, Glynn S et al. 2016. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br. J. Psychiatry 209:192–201
    [Google Scholar]
  63. Hamilton HK, Roach BJ, Bachman PM, Belger A, Carrion RE et al. 2019. Association between P300 responses to auditory oddball stimuli and clinical outcomes in the psychosis risk syndrome. JAMA Psychiatry 76:1187–97
    [Google Scholar]
  64. Hamilton HK, Roach BJ, Mathalon DH. 2021. Forecasting remission from the psychosis risk syndrome with mismatch negativity and P300: potentials and pitfalls. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 6:178–87
    [Google Scholar]
  65. Hartmann JA, Nelson B, Ratheesh A, Treen D, McGorry PD. 2019. At-risk studies and clinical antecedents of psychosis, bipolar disorder and depression: a scoping review in the context of clinical staging. Psychol. Med. 49:177–89
    [Google Scholar]
  66. Hermens DF, Naismith SL, Lagopoulos J, Lee RSC, Guastella AJ et al. 2013. Neuropsychological profile according to the clinical stage of young persons presenting for mental health care. BMC Psychol 1:8
    [Google Scholar]
  67. Hermens DF, Ward PB, Hodge MAR, Kaur M, Naismith SL, Hickie IB. 2010. Impaired MMN/P3a complex in first-episode psychosis: cognitive and psychosocial associations. Prog. Neuropsychopharmacol. Biol. Psychiatry 34:822–29
    [Google Scholar]
  68. Hetrick SE, Bailey AP, Smith KE, Malla A, Mathias S et al. 2017. Integrated (one-stop shop) youth health care: best available evidence and future directions. Med. J. Aust. 207:S5–18
    [Google Scholar]
  69. Hetrick SE, Parker AG, Hickie IB, Purcell R, Yung AR, McGorry PD. 2008. Early identification and intervention in depressive disorders towards a clinical staging model. Psychother. Psychosom. 77:263–70
    [Google Scholar]
  70. Hickie IB, Scott EM, Cross SP, Iorfino F, Davenport TA et al. 2019. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health. Med. J. Aust. 211:S3–46
    [Google Scholar]
  71. Hickie IB, Scott EM, Hermens DF, Naismith SL, Guastella AJ et al. 2013a. Applying clinical staging to young people who present for mental health care. Early Interv. Psychiatry 7:31–43
    [Google Scholar]
  72. Hickie IB, Scott J, Hermens DF, Scott EM, Naismith SL et al. 2013b. Clinical classification in mental health at the cross-roads: which direction next?. BMC Med 11:125
    [Google Scholar]
  73. Iffland K, Grotenhermen F. 2017. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res 2:139–54
    [Google Scholar]
  74. Inst. Med 2001. Crossing the Quality Chasm: a New Health System for the 21st Century Washington, DC: Natl. Acad. Press
    [Google Scholar]
  75. Iorfino F, Scott EM, Carpenter JS, Cross SP, Hermens DF et al. 2019. Clinical stage transitions in persons aged 12 to 25 years presenting to early intervention mental health services with anxiety, mood, and psychotic disorders. JAMA Psychiatry 76:1167–75
    [Google Scholar]
  76. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW et al. 2009. Brain-derived neurotrophic factor and inflammatory markers in patients with early- versus late-stage bipolar disorder. Int. J. Neuropsychopharmacol. 12:447–58
    [Google Scholar]
  77. Kendell R, Jablensky A. 2003. Distinguishing between the validity and utility of psychiatric diagnoses. Am. J. Psychiatry 160:4–12
    [Google Scholar]
  78. Kendler KS. 2018. Classification of psychopathology: conceptual and historical background. World Psychiatry 17:241–42
    [Google Scholar]
  79. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE 2005. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch. Gen. Psychiatry 62:593–602
    [Google Scholar]
  80. Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB. 2015. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2:258–70
    [Google Scholar]
  81. Kiecolt-Glaser JK, Epel ES, Belury MA, Andridge R, Lin J et al. 2013. Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: a randomized controlled trial. Brain Behav. Immun. 28:16–24
    [Google Scholar]
  82. Killackey E, Hodges C, Browne V, Gow E, Varnum P et al. 2020. A global framework for youth mental health: investing in future mental capital for individuals, communities and economies Rep., World Econ. Forum Geneva, Switz:.
    [Google Scholar]
  83. Kotov R, Krueger RF, Watson D, Cicero DC, Conway CC et al. 2021. The Hierarchical Taxonomy of Psychopathology (HiTOP): a quantitative nosology based on consensus of evidence. Annu. Rev. Clin. Psychol. 17:83–108
    [Google Scholar]
  84. Kozak MJ, Cuthbert BN. 2016. The NIMH Research Domain Criteria initiative: background, issues, and pragmatics. Psychophysiology 53:286–97
    [Google Scholar]
  85. Lagopoulos J, Hermens DF, Hatton SN, Battisti RA, Tobias-Webb J et al. 2013. Microstructural white matter changes are correlated with the stage of psychiatric illness. Transl. Psychiatry 3:e248
    [Google Scholar]
  86. Lagopoulos J, Hermens DF, Naismith SL, Scott EM, Hickie IB. 2012. Frontal lobe changes occur early in the course of affective disorders in young people. BMC Psychiatry 12:4
    [Google Scholar]
  87. Lal S, Adair CE. 2014. E-mental health: a rapid review of the literature. Psychiatr. Serv. 65:24–32
    [Google Scholar]
  88. Lavoie S, Berger M, Schlögelhofer M, Schäfer MR, Rice S et al. 2017. Erythrocyte glutathione levels as long-term predictor of transition to psychosis. Transl. Psychiatry 7:e1064
    [Google Scholar]
  89. Lavoie S, Jack BN, Griffiths O, Ando A, Amminger P et al. 2018. Impaired mismatch negativity to frequency deviants in individuals at ultra-high risk for psychosis, and preliminary evidence for further impairment with transition to psychosis. Schizophr. Res. 191:95–100
    [Google Scholar]
  90. Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M et al. 2008. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 33:2187–99
    [Google Scholar]
  91. Lavoie S, Polari AR, Goldstone S, Nelson B, McGorry PD 2019. Staging model in psychiatry: review of the evolution of electroencephalography abnormalities in major psychiatric disorders. Early Interv. Psychiatry 13:1319–28
    [Google Scholar]
  92. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW et al. 2012. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2:e94
    [Google Scholar]
  93. Maalouf FT, Atwi M, Brent DA. 2011. Treatment-resistant depression in adolescents: review and updates on clinical management. Depress. Anxiety 28:946–54
    [Google Scholar]
  94. Maj M. 2020. Beyond diagnosis in psychiatric practice. Ann. Gen. Psychiatry 19:27
    [Google Scholar]
  95. Mathalon DH, Ford JM, Rosenbloom M, Pfefferbaum A. 2000. P300 reduction and prolongation with illness duration in schizophrenia. Biol. Psychiatry 47:413–27
    [Google Scholar]
  96. McGorry P, Keshavan M, Goldstone S, Amminger P, Allott K et al. 2014a. Biomarkers and clinical staging in psychiatry. World Psychiatry 13:211–23
    [Google Scholar]
  97. McGorry P, Nelson B. 2016. Why we need a transdiagnostic staging approach to emerging psychopathology, early diagnosis, and treatment. JAMA Psychiatry 73:191–92
    [Google Scholar]
  98. McGorry P, van Os J. 2013. Redeeming diagnosis in psychiatry: timing versus specificity. Lancet 381:343–45
    [Google Scholar]
  99. McGorry PD. 2013. The next stage for diagnosis: validity through utility. World Psychiatry 12:213–15
    [Google Scholar]
  100. McGorry PD, Goldstone SD, Parker AG, Rickwood DJ, Hickie IB. 2014b. Cultures for mental health care of young people: an Australian blueprint for reform. Lancet Psychiatry 1:559–68
    [Google Scholar]
  101. McGorry PD, Hartmann JA, Spooner R, Nelson B 2018. Beyond the “at risk mental state” concept: transitioning to transdiagnostic psychiatry. World Psychiatry 17:133–42
    [Google Scholar]
  102. McGorry PD, Hickie IB 2019. Clinical Staging in Psychiatry: Making Diagnosis Work for Research and Treatment Cambridge, UK: Cambridge Univ. Press
    [Google Scholar]
  103. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. 2006. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safe and more effective interventions. Aust. N. Z. J. Psychiatry 40:616–22
    [Google Scholar]
  104. McGorry PD, Nelson B, Markulev C, Yuen HP, Schäfer MR et al. 2017. Effect of ω-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiatry 74:19–27
    [Google Scholar]
  105. McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD et al. 2017. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am. J. Psychiatry 175:225–31
    [Google Scholar]
  106. McNamara RK, Jandacek R, Tso P, Blom TJ, Welge JA et al. 2016. Adolescents with or at ultra-high risk for bipolar disorder exhibit erythrocyte docosahexaenoic acid and eicosapentaenoic acid deficits: a candidate prodromal risk biomarker. Early Interv. Psychiatry 10:203–11
    [Google Scholar]
  107. McTeague LM, Goodkind MS, Etkin A. 2016. Transdiagnostic impairment of cognitive control in mental illness. J. Psychiatr. Res. 83:37–46
    [Google Scholar]
  108. Metzak PD, Addington J, Hassel S, Goldstein BI, MacIntosh BJ et al. 2021. Functional imaging in youth at risk for transdiagnostic serious mental illness: initial results from the PROCAN study. Early Interv. Psychiatry 15:127691
    [Google Scholar]
  109. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. 2011. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 70:663–71
    [Google Scholar]
  110. Naismith SL, Hermens DF, Ip TKC, Bolitho S, Scott E et al. 2012. Circadian profiles in young people during the early stages of affective disorder. Transl. Psychiatry 2:e123
    [Google Scholar]
  111. Naismith SL, Lagopoulos J, Hermens DF, White D, Duffy SL et al. 2014. Delayed circadian phase is linked to glutamatergic functions in young people with affective disorders: a proton magnetic resonance spectroscopy study. BMC Psychiatry 14:345
    [Google Scholar]
  112. Natl. Res. Counc 2011. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease Washington, DC: Natl. Acad. Press
    [Google Scholar]
  113. Nelson B, McGorry PD, Wichers M, Wigman JTW, Hartmann JA. 2017. Moving from static to dynamic models of the onset of mental disorder: a review. JAMA Psychiatry 74:528–34
    [Google Scholar]
  114. Ng F, Berk M, Dean O, Bush AI. 2008. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 11:851–76
    [Google Scholar]
  115. Nogovitsyn N, Souza R, Muller M, Srajer A, Metzak PD et al. 2020. Aberrant limbic brain structures in young individuals at risk for mental illness. Psychiatry Clin. Neurosci. 74:294–302
    [Google Scholar]
  116. Nordholm D, Poulsen HE, Hjorthøj C, Randers L, Nielsen et al. 2016. Systemic oxidative DNA and RNA damage are not increased during early phases of psychosis: a case control study. Psychiatry Res 241:201–6
    [Google Scholar]
  117. O'Dea B, Glozier N, Purcell R, McGorry PD, Scott J et al. 2014. A cross-sectional exploration of the clinical characteristics of disengaged (NEET) young people in primary mental healthcare. BMJ Open 4:e006378
    [Google Scholar]
  118. Ospina-Pinillos L, Davenport T, Iorfino F, Tickell A, Cross S et al. 2018. Using new and innovative technologies to assess clinical stage in early intervention youth mental health services: evaluation study. J. Med. Internet Res. 20:e259
    [Google Scholar]
  119. Özgürdal S, Gudlowski Y, Witthaus H, Kawohl W, Uhl I et al. 2008. Reduction of auditory event-related P300 amplitude in subjects with at-risk mental state for schizophrenia. Schizophr. Res. 105:272–78
    [Google Scholar]
  120. Parker N, Patel Y, Jackowski AP, Pan PM, Salum GA et al. 2020. Assessment of neurobiological mechanisms of cortical thinning during childhood and adolescence and their implications for psychiatric disorders. JAMA Psychiatry 77:1127–36
    [Google Scholar]
  121. Paus T, Keshavan M, Giedd JN. 2008. Why do many psychiatric disorders emerge during adolescence?. Nat. Rev. Neurosci. 9:947–57
    [Google Scholar]
  122. Pinto JV, Saraf G, Frysch C, Vigo D, Keramatian K et al. 2020. Cannabidiol as a treatment for mood disorders: a systematic review. Can. J. Psychiatry 65:213–27
    [Google Scholar]
  123. Plana-Ripoll O, Pedersen CB, Holtz Y, Benros ME, Dalsgaard S et al. 2019. Exploring comorbidity within mental disorders among a Danish national population. JAMA Psychiatry 76:259–70
    [Google Scholar]
  124. Pot-Kolder RMCA, Geraets CNW, Veling W, van Beilen M, Staring ABP et al. 2018. Virtual-reality-based cognitive behavioural therapy versus waiting list control for paranoid ideation and social avoidance in patients with psychotic disorders: a single-blind randomised controlled trial. Lancet Psychiatry 5:217–26
    [Google Scholar]
  125. Purcell R, Jorm AF, Hickie IB, Yung AR, Pantelis C et al. 2015. Demographic and clinical characteristics of young people seeking help at youth mental health services: baseline findings of the Transitions Study. Early Interv. Psychiatry 9:487–97
    [Google Scholar]
  126. Reichenberg A, Caspi A, Harrington H, Houts R, Keefe RSE et al. 2010. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am. J. Psychiatry 167:160–69
    [Google Scholar]
  127. Rice S, Gleeson J, Davey C, Hetrick S, Parker A et al. 2018. Moderated online social therapy for depression relapse prevention in young people: pilot study of a ‘next generation’ online intervention. Early Interv. Psychiatry 12:613–25
    [Google Scholar]
  128. Rice SM, Schäfer MR, Klier C, Mossaheb N, Vijayakumar N, Amminger GP. 2015. Erythrocyte polyunsaturated fatty acid levels in young people at ultra-high risk for psychotic disorder and healthy adolescent controls. Psychiatry Res 228:174–76
    [Google Scholar]
  129. Rickwood D, Paraskakis M, Quin D, Hobbs N, Ryall V et al. 2019. Australia's innovation in youth mental health care: the headspace centre model. Early Interv. Psychiatry 13:159–66
    [Google Scholar]
  130. Robertson OD, Coronado NG, Sethi R, Berk M, Dodd S 2019. Putative neuroprotective pharmacotherapies to target the staged progression of mental illness. Early Interv. Psychiatry 13:1032–49
    [Google Scholar]
  131. Robillard R, Hermens DF, Lee RS, Jones A, Carpenter JS et al. 2016. Sleep-wake profiles predict longitudinal changes in manic symptoms and memory in young people with mood disorders. J. Sleep Res. 25:549–55
    [Google Scholar]
  132. Robillard R, Naismith SL, Rogers NL, Scott EM, Ip TKC et al. 2013a. Sleep-wake cycle and melatonin rhythms in adolescents and young adults with mood disorders: comparison of unipolar and bipolar phenotypes. Eur. Psychiatry 28:412–6
    [Google Scholar]
  133. Robillard R, Naismith SL, Rogers NL, Ip TKC, Hermens DF et al. 2013b. Delayed sleep phase in young people with unipolar or bipolar affective disorders. J. Affect. Disord. 145:260–63
    [Google Scholar]
  134. Rohleder C, Crouse JJ, Carpenter JS, Iorfino F, Cross SP et al. 2019. Personalising care options in youth mental health: using multidimensional assessment, clinical stage, pathophysiological mechanisms, and individual illness trajectories to guide treatment selection. Med. J. Aust. 211:S32–41
    [Google Scholar]
  135. Romanowska S, MacQueen G, Goldstein BI, Wang J, Kennedy SH et al. 2018. Neurocognitive deficits in a transdiagnostic clinical staging model. Psychiatry Res 270:1137–42
    [Google Scholar]
  136. Sacks DD, Lagopoulos J, Hatton SN, Iorfino F, Carpenter JS et al. 2021. White matter integrity according to the stage of mental disorder in youth. Psychiatry Res. Neuroimaging 307:111218
    [Google Scholar]
  137. Scott EM, Robillard R, Hermens DF, Naismith SL, Rogers NL et al. 2016. Dysregulated sleep–wake cycles in young people are associated with emerging stages of major mental disorders. Early Interv. Psychiatry 10:63–70
    [Google Scholar]
  138. Sha Z, Wager TD, Mechelli A, He Y. 2019. Common dysfunction of large-scale neurocognitive networks across psychiatric disorders. Biol. Psychiatry 85:379–88
    [Google Scholar]
  139. Shah JL, Scott J, McGorry PD, Cross SPM, Keshavan MS et al. 2020. Transdiagnostic clinical staging in youth mental health: a first international consensus statement. World Psychiatry 19:233–42
    [Google Scholar]
  140. Shakeel MK, MacQueen G, Addington J, Metzak PD, Georgopoulos G et al. 2020. White matter connectivity in youth at risk for serious mental illness: a longitudinal analysis. Psychiatry Res. Neuroimaging 302:111106
    [Google Scholar]
  141. Smesny S, Kinder D, Willhardt I, Rosburg T, Lasch J et al. 2005. Increased calcium-independent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia. Biol. Psychiatry 57:399–405
    [Google Scholar]
  142. Smesny S, Milleit B, Hipler UC, Milleit C, Schäfer MR et al. 2014. Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. Mol. Psychiatry 19:317–24
    [Google Scholar]
  143. Smesny S, Milleit B, Nenadic I, Preul C, Kinder D et al. 2010. Phospholipase A2 activity is associated with structural brain changes in schizophrenia. NeuroImage 52:1314–27
    [Google Scholar]
  144. Stephan KE, Bach DR, Fletcher PC, Flint J, Frank MJ et al. 2016. Charting the landscape of priority problems in psychiatry, part 1: classification and diagnosis. Lancet Psychiatry 3:77–83
    [Google Scholar]
  145. Stowkowy J, Brummitt K, Bonneville D, Goldstein BI, Wang J et al. 2020. Sleep disturbances in youth at-risk for serious mental illness. Early Interv. Psychiatry 14:373–78
    [Google Scholar]
  146. Su K-P, Tseng P-T, Lin P-Y, Okubo R, Chen T-Y et al. 2018. Association of use of omega-3 polyunsaturated fatty acids with changes in severity of anxiety symptoms: a systematic review and meta-analysis. JAMA Netw. Open 1:e182327
    [Google Scholar]
  147. Sublette ME, Galfalvy HC, Hibbeln JR, Keilp JG, Malone KM et al. 2014. Polyunsaturated fatty acid associations with dopaminergic indices in major depressive disorder. Int. J. Neuropsychopharmacol. 17:383–91
    [Google Scholar]
  148. Tang Y, Wang J, Zhang T, Xu L, Qian Z et al. 2020. P300 as an index of transition to psychosis and of remission: data from a clinical high risk for psychosis study and review of literature. Schizophr. Res. 226:74–83
    [Google Scholar]
  149. Tickell AM, Lee RSC, Hickie IB, Hermens DF. 2019. The course of neuropsychological functioning in young people with attenuated versus discrete mental disorders. Early Interv. Psychiatry 13:425–33
    [Google Scholar]
  150. Torous J, Nicholas J, Larsen ME, Firth J, Christensen H. 2018. Clinical review of user engagement with mental health smartphone apps: evidence, theory and improvements. Evid. Based Ment. Health 21:116–19
    [Google Scholar]
  151. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. 2007. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr. Bull. 33:69–94
    [Google Scholar]
  152. Umbricht D, Krljes S. 2005. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr. Res. 76:1–23
    [Google Scholar]
  153. Upthegrove R, Khandaker GM 2020. Cytokines, oxidative stress and cellular markers of inflammation in schizophrenia. Neuroinflammation and Schizophrenia GM Khandaker, U Meyer, PB Jones 49–66 Cham, Switz: Springer Int. Publ.
    [Google Scholar]
  154. Valmaggia LR, Latif L, Kempton MJ, Rus-Calafell M. 2016. Virtual reality in the psychological treatment for mental health problems: an systematic review of recent evidence. Psychiatry Res 236:189–95
    [Google Scholar]
  155. van der Kemp WJM, Klomp DWJ, Kahn RS, Luijten PR, Hulshoff Pol HE 2012. A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia. Schizophr. Res. 141:153–61
    [Google Scholar]
  156. van der Stelt O, Lieberman JA, Belger A. 2005. Auditory P300 in high-risk, recent-onset and chronic schizophrenia. Schizophr. Res. 77:309–20
    [Google Scholar]
  157. van Os J. 2013. The dynamics of subthreshold psychopathology: implications for diagnosis and treatment. Am. J. Psychiatry 170:695–98
    [Google Scholar]
  158. Velthorst E, Mollon J, Murray RM, de Haan L, Germeys IM et al. 2021. Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Mol. Psychiatry press. https://doi.org/10.1038/s41380-020-00969-z
    [Crossref] [Google Scholar]
  159. Wigman JT, van Os J, Thiery E, Derom C, Collip D et al. 2013. Psychiatric diagnosis revisited: towards a system of staging and profiling combining nomothetic and idiographic parameters of momentary mental states. PLOS ONE 8:e59559
    [Google Scholar]
  160. Wright JR Jr. 2012. Albert C. Broders' paradigm shifts involving the prognostication and definition of cancer. Arch. Pathol. Lab. Med. 136:1437–46
    [Google Scholar]
  161. Yolland COB, Hanratty D, Neill E, Rossell SL, Berk M et al. 2019. Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia. Aust. N. Z. J. Psychiatry 54:453–66
    [Google Scholar]
/content/journals/10.1146/annurev-devpsych-050620-030405
Loading
/content/journals/10.1146/annurev-devpsych-050620-030405
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error